Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer

Area of Science:

• Oncology
• Genomics
• Precision Medicine

Background:

• Epidermal growth factor receptor (EGFR) inhibitors have revolutionized non-small-cell lung cancer (NSCLC) treatment.
• Somatic EGFR mutations are key biomarkers for treatment response and resistance.
• Primary and acquired resistance limit the efficacy of first-generation EGFR inhibitors, occurring in 10-30% of patients.

Purpose of the Study:

• To review strategies for overcoming T790M-mediated resistance to EGFR inhibitors.
• To focus on the clinical development and efficacy of second-generation EGFR inhibitors, specifically afatinib.
• To discuss the emergence of third-generation EGFR inhibitors and future management of EGFR-mutant lung adenocarcinoma.

Main Methods:

• Review of strategies to circumvent T790M resistance.
• Analysis of clinical development, efficacy, and toxicity of afatinib (BIBW2992).
• Discussion of LUX-Lung studies and third-generation EGFR inhibitors.

Main Results:

• T790M mutation is the most common mechanism of acquired resistance to EGFR inhibitors.
• Second-generation inhibitors like afatinib demonstrate clinical efficacy in overcoming resistance.
• Ongoing development of third-generation inhibitors promises further therapeutic advancements.

Conclusions:

• Targeting EGFR mutations with successive generations of inhibitors is crucial for managing NSCLC.
• Afatinib represents a significant advancement in overcoming acquired resistance.
• Future strategies involve mutant-selective inhibitors for improved and durable responses in EGFR-mutant lung adenocarcinoma.